Hemispherex Investors Put Anti-Fatigue Drug Suit To Rest
Hemispherx Biopharma Inc. shareholders have settled a consolidated Pennsylvania derivative suit alleging the company's directors and officers misrepresented the safety and efficacy of the anti-fatigue drug Ampligen and overstated its prospects...To view the full article, register now.
Already a subscriber? Click here to view full article